Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rufinamide in refractory partial onset seizures
NCT00448539Phase 3
Key facts
- Status
- Terminated
- Start
- Mar 2007
- Primary completion
- May 2010
- Countries
- 1
- Sponsor
- Eisai Co., Ltd.
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Drugs
- rufinamide
- Conditions
- focal onset seizure
01
Overview
Phase 3, open-label trial of rufinamide in focal onset seizure, sponsored by Eisai Co., Ltd. Primary endpoint: Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase. Started Mar 2007; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-label
03
Endpoints
Primary
Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase
Beyond the preview
Go deeper on NCT00448539.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448539.